过继性 T 细胞疗法：增强免疫系统以对抗癌症。
Adoptive T cell therapy: Boosting the immune system to fight cancer.
机构信息
Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States.
出版信息
Semin Immunol. 2020 Jun;49:101437. doi: 10.1016/j.smim.2020.101437. Epub 2020 Nov 29.
Abstract
Cellular therapies have shown increasing promise as a cancer treatment. Encouraging results against hematologic malignancies are paving the way to move into solid tumors. In this review, we will focus on T-cell therapies starting from tumor infiltrating lymphocytes (TILs) to optimized T-cell receptor-modified (TCR) cells and chimeric antigen receptor-modified T cells (CAR-Ts). We will discuss the positive preclinical and clinical findings of these approaches, along with some of the persisting barriers that need to be overcome to improve outcomes.
摘要
细胞疗法作为癌症治疗方法的前景日益广阔。针对血液恶性肿瘤的可喜结果为进入实体肿瘤铺平了道路。在这篇综述中，我们将重点介绍从肿瘤浸润淋巴细胞 (TIL) 到优化的 T 细胞受体修饰 (TCR) 细胞和嵌合抗原受体修饰 T 细胞 (CAR-T) 的 T 细胞疗法。我们将讨论这些方法的积极临床前和临床发现，以及需要克服的一些持续存在的障碍，以改善治疗效果。
相似文献
1
Adoptive T cell therapy: Boosting the immune system to fight cancer.
Semin Immunol. 2020 Jun;49:101437. doi: 10.1016/j.smim.2020.101437. Epub 2020 Nov 29.
2
Future perspectives on engineered T cells for cancer.
Trends Cancer. 2024 Aug;10(8):687-695. doi: 10.1016/j.trecan.2024.05.007. Epub 2024 Jun 8.
3
Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
J Immunol Res. 2017;2017:5210459. doi: 10.1155/2017/5210459. Epub 2017 Jan 2.
4
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Sci China Life Sci. 2016 Apr;59(4):340-8. doi: 10.1007/s11427-016-5027-4. Epub 2016 Mar 11.
5
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
6
Improving the efficacy and safety of engineered T cell therapy for cancer.
Cancer Lett. 2013 Jan 28;328(2):191-7. doi: 10.1016/j.canlet.2012.09.015. Epub 2012 Sep 27.
7
CAR T Cell Therapy for Solid Tumors.
Annu Rev Med. 2017 Jan 14;68:139-152. doi: 10.1146/annurev-med-062315-120245. Epub 2016 Nov 17.
8
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Mol Immunol. 2015 Oct;67(2 Pt A):46-57. doi: 10.1016/j.molimm.2014.12.009. Epub 2015 Jan 13.
9
Paving New Roads for CARs.
Trends Cancer. 2019 Oct;5(10):583-592. doi: 10.1016/j.trecan.2019.09.005. Epub 2019 Oct 19.
10
T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
Cancer J. 2019 May/Jun;25(3):179-190. doi: 10.1097/PPO.0000000000000378.
引用本文的文献
1
Comprehensive pan-cancer multi-omics analysis of ATAD2 in human cancers.
Medicine (Baltimore). 2025 Jul 18;104(29):e42396. doi: 10.1097/MD.0000000000042396.
2
Characterization of T cell proliferation-associated hepatocellular carcinoma subtypes, predictive signatures, and candidate targets.
J Gastrointest Oncol. 2025 Jun 30;16(3):1127-1143. doi: 10.21037/jgo-2025-50. Epub 2025 Jun 27.
3
T cells in cancer: mechanistic insights and therapeutic advances.
Biomark Res. 2025 Jul 15;13(1):97. doi: 10.1186/s40364-025-00807-w.
4
Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool.
Probiotics Antimicrob Proteins. 2025 Feb 15. doi: 10.1007/s12602-025-10468-8.
5
A novel necroptosis-related gene signature predicts the prognosis and immunotherapeutic response in breast cancer through immune infiltration.
Discov Oncol. 2025 Jan 10;16(1):31. doi: 10.1007/s12672-025-01770-6.
6
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells.
Cancers (Basel). 2024 Jul 7;16(13):2478. doi: 10.3390/cancers16132478.
7
Applications of self-assembled peptide hydrogels in anti-tumor therapy.
Nanoscale Adv. 2024 Apr 30;6(12):2993-3008. doi: 10.1039/d4na00172a. eCollection 2024 Jun 11.
8
Trichostatin A-modified vaccine provides superior protection against ovarian cancer formation and development.
Braz J Med Biol Res. 2024 May 17;57:e12874. doi: 10.1590/1414-431X2024e12874. eCollection 2024.
9
CD8 T cell-based cancer immunotherapy.
J Transl Med. 2024 Apr 29;22(1):394. doi: 10.1186/s12967-024-05134-6.
10
Identification of novel T cell proliferation patterns, potential biomarkers and therapeutic drugs in colorectal cancer.
J Cancer. 2024 Jan 1;15(5):1234-1254. doi: 10.7150/jca.91835. eCollection 2024.
本文引用的文献
1
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
Blood Cancer Discov. 2020 Sep;1(2):146-154. doi: 10.1158/2643-3230.BCD-20-0020.
2
Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion.
Clin Cancer Res. 2020 Oct 15;26(20):5494-5505. doi: 10.1158/1078-0432.CCR-20-0777. Epub 2020 Aug 14.
3
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.
4
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.
Front Oncol. 2020 May 6;10:697. doi: 10.3389/fonc.2020.00697. eCollection 2020.
5
Tuning the Antigen Density Requirement for CAR T-cell Activity.
Cancer Discov. 2020 May;10(5):702-723. doi: 10.1158/2159-8290.CD-19-0945. Epub 2020 Mar 19.
6
Interleukin-23 engineering improves CAR T cell function in solid tumors.
Nat Biotechnol. 2020 Apr;38(4):448-459. doi: 10.1038/s41587-019-0398-2. Epub 2020 Feb 3.
7
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
Cancer Cell. 2020 Feb 10;37(2):216-225.e6. doi: 10.1016/j.ccell.2019.12.014. Epub 2020 Jan 30.
8
A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
Cancer Immunol Res. 2020 Jan;8(1):57-69. doi: 10.1158/2326-6066.CIR-19-0134. Epub 2019 Nov 12.
9
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
Clin Pharmacol Ther. 2020 Jan;107(1):112-122. doi: 10.1002/cpt.1674. Epub 2019 Nov 25.
10
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Clin Cancer Res. 2019 Dec 15;25(24):7506-7516. doi: 10.1158/1078-0432.CCR-19-1479. Epub 2019 Sep 23.
Zotero 插件